Top
image credit: The U.S. Food and Drug Administration / Wikimedia

FDA ad police’s warning letters have stalled during COVID-19, and that’s likely the new norm: expert

August 5, 2020

Category:

Enforcement letter output from the FDA’s advertising watchdog has slowed to zero during the COVID-19 pandemic. Only one letter from Office of Prescription Drug Promotion (OPDP) has been sent in 2020, and that was back in February, before the pandemic shutdowns began.

While COVID-19 is partly to blame, OPDP letter activity likely won’t pick up much even after the pandemic clears, says a veteran FDA watcher.

While the FDA, OPDP’s parent, certainly has bigger issues to deal with during the current coronavirus crisis, the slowdown of warning and untitled letters has been a larger and ongoing trend in general, said Eye on FDA blogger and public relations professional Mark Senak.

Read More on FiercePharma